At a glance
ClinicalIndex Comparison RecordPhase 2Active· 4 enrolled
Drug / intervention
Trametinib Dimethyl Sulfoxidedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
MATCH Treatment Subprotocol S2: Phase II Study of Trametinib in Patients With Tumors With GNAQ or GNA11 Mutations
In Brief
A Phase 2 clinical trial evaluating Trametinib Dimethyl Sulfoxide for Advanced Lymphoma and 5 related conditions. Active but no longer recruiting, targeting 4 participants across 1 site.
Detailed Summary
This phase II MATCH treatment trial identifies the effects of trametinib in patients whose cancer has genetic changes called GNAQ or GNA11 mutations. Trametinib may block proteins called MEK1 and MEK2, which may be needed for cancer cell growth when GNAQ or GNA11 mutations are present. Researchers hope to learn if trametinib will shrink this type of cancer or stop its growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
CountriesUnited States
Collaborators--
Timeline
Phase 2Active
201620172018201920202021202220232024202520262027
Enrollment StartFeb 2016
First PostedJun 2020
Primary CompletionSep 2020
TodayJul 2026
Study CompletionJan 2027
First PostedJun 19, 2020
Enrollment StartFeb 25, 2016
Primary CompletionSep 1, 2020
Study CompletionJan 15, 2027
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 6.0 years ago
Interventions
Trametinib Dimethyl Sulfoxidedrug
Given PO